Dotmatics

Dotmatics provides scientific software solutions that connect science, data, and decision-making for life sciences R&D organizations. The company serves more than 2 million researchers across 14,000+ customers globally, providing end-to-end solutions for biologics discovery, small-molecule chemistry, chemicals and materials science, and flow cytometry applications.

The company was formed in March 2021 when Insightful Science acquired the original Dotmatics company (founded by former Merck scientists) in a $690 million transaction. The combined entity, with over 800 employees globally, rebranded to Dotmatics in April 2022. In April 2025, Siemens AG announced the acquisition of Dotmatics for $5.1 billion, completing the purchase three months later in July 2025.

Dotmatics' product portfolio includes the Luma Scientific Intelligence Platform, scientific tools including GraphPad Prism (statistical analysis), SnapGene (molecular biology), Geneious Prime and Biologics (bioinformatics), FCS Express and OMIQ (flow cytometry), as well as its core ELN & Data Discovery Platform, Vortex (cheminformatics), and LabArchives.

The company operates from 14 offices globally with R&D teams distributed across multiple regions, serving customers in more than 180 countries. Dotmatics is backed by Insight Partners (prior to Siemens acquisition) and has grown through strategic acquisitions to build a platform for scientific data management and analysis.

14,000+ customers and 2 million researchers globally use Dotmatics solutions across pharmaceutical and life sciences organizations. The company's product portfolio is designed for drug discovery and development workflows across biologics, small molecules, and analytical sciences.

Notable pharmaceutical and biotech customers include Charles River Laboratories (deployed to 500 researchers), Krystal Biotech (rare disease gene therapy), Lead Pharma, and a mass-spec core facility at a large pharma company. The customer base spans Big Pharma, biotech, contract research organizations (CROs), and academic institutions.

The company works directly with pharmaceutical companies to help navigate GxP processes and integrate compliance requirements into research workflows. Dotmatics solutions support FDA 21 CFR Part 11, GMP, GLP, and GCP compliance requirements, with GAMP 5 Category 4 classification and validation support.

Pharmaceutical and biotech R&D is a core focus area within a broader life sciences and materials science customer base. The platform's capabilities for chemical registration, biological data management, ELN, LIMS, and data discovery are purpose-built for drug development workflows from early discovery through clinical stages.

Siemens AG acquired Dotmatics for $5.1 billion, announced in April 2025 and completed in July 2025.

The current Dotmatics entity was formed in March 2021 when Insightful Science acquired the original Dotmatics company in a $690 million transaction. Prior to the Siemens acquisition, Dotmatics was backed by Insight Partners, a global software investor.

The company grew through strategic acquisitions, building a portfolio that includes GraphPad Prism, SnapGene, Geneious, FCS Express, OMIQ, Protein Metrics, LabArchives, and other scientific software tools. The original Dotmatics team of 300+ scientists, software developers, engineers, and project managers combined with Insightful Science to create an 800+ person organization.

Revenue and revenue growth are undisclosed.

Dotmatics offers a portfolio of scientific software solutions organized around several flagship products:

**Luma Scientific Intelligence Platform**: AI-powered multimodal research platform with adaptive workflows, low-code SaaS deployment, and integration with 100+ lab instruments. Supports FAIR data principles and AI readiness for organizations.

**ELN & Data Discovery Platform**: Core electronic laboratory notebook with chemical registration (Register), biological registration (Bioregister), federated data search (Browser), and Lab Connect instrument integration.

**Statistical & Data Analysis**: GraphPad Prism (statistical analysis and graphing), Protein Metrics (proteomics analysis), nQuery (sample size calculation).

**Molecular Biology & Bioinformatics**: SnapGene (molecular biology), Geneious Prime and Geneious Biologics (sequence analysis), SoftGenetics (genetic analysis), Virscidian (viral vector analytics).

**Flow Cytometry**: OMIQ (cloud-based flow cytometry analysis), FCS Express (flow cytometry software).

**Cheminformatics**: Vortex (chemical data analysis and visualization).

**Additional Tools**: LabArchives (ELN alternative), M-Star (protein formulation), EasyPanel (flow cytometry panel design), Lab Connect (instrument data integration).

The product strategy emphasizes an integrated platform approach where tools work together across the R&D workflow, from experimental design through data analysis and decision-making. Cloud-native architecture, AI capabilities, and instrument integration characterize the platform. Dotmatics offers modular deployment, allowing customers to adopt individual tools or suites based on their needs.

Dotmatics maintains an integration ecosystem supporting connection to 100+ lab instruments through its Lab Connect platform. The company's Luma platform emphasizes data integration across multiple sources including instruments, databases, and scientific applications.

Technology partnerships and integrations span LIMS systems, screening tools, analytics platforms, and third-party databases. The platform supports federated data search allowing customers to integrate Dotmatics tools with existing infrastructure and external data sources.

The company pursued a growth strategy through strategic acquisitions, integrating GraphPad, SnapGene, Geneious, OMIQ, FCS Express, Protein Metrics, LabArchives and other specialized scientific software companies into a unified platform. The ecosystem was built through this M&A approach rather than through reliance on third-party partnerships.

As a subsidiary of Siemens AG (acquired 2025), integration with Siemens' broader enterprise software and industrial partnerships is undisclosed.

Dotmatics provides professional services including implementation support, validation assistance, training, and customer success programs. The company works with customers to configure software based on industry best practices while maintaining regulatory compliance.

For GAMP 5 Category 4 products like Dotmatics ELN, the vendor supports customer-led validation efforts by providing validation documentation and expertise to help customers meet FDA 21 CFR Part 11 and GxP requirements. Implementation services include workflow configuration, data migration, and integration with existing laboratory systems.

800+ employees across 21 countries support customers in 180+ countries through Dotmatics' global support organization. 24/7 support availability, regional coverage, and language support are undisclosed.

The company hosts user symposiums and events for customer engagement and knowledge sharing. Customer collaboration informed recent platform improvements including the enhanced user interface and simplified navigation released in the ELN & Data Discovery Platform 7.1 update.

Certification programs, user community forums, and detailed support availability by region are undisclosed.

Dotmatics holds ISO 9001 and ISO 27001 certifications, a GAMP 5 compliance classification, and FDA 21 CFR Part 11 regulatory support material. The company provides AES-256 encryption and maintains a self-service Trust Center for security transparency.

Siemens AG acquired Dotmatics for $5.1 billion in 2025. Insight Partners, a global software investor, backed the company prior to the Siemens acquisition.

Leadership includes CEO Thomas Swalla (appointed when Insightful Science and Dotmatics merged in 2021). The original Dotmatics company was founded by former Merck scientists.

14,000+ customers and 2 million researchers use Dotmatics solutions globally. The customer base includes named pharmaceutical and biotech companies such as Charles River Laboratories and Krystal Biotech, plus academic institutions through academic licensing programs.

Thought leadership activities include customer symposiums, product webinars, and a company blog covering topics like ELN adoption, data management best practices, and regulatory compliance. The company publishes case studies describing customer implementations across pharmaceutical, biotech, and academic research organizations.

Dotmatics maintains an active market presence through regular product updates, customer case studies, and industry engagement. Recent announcements include the ELN & Data Discovery Platform 7.1 release with enhanced user interface and simplified navigation, and the Small Molecule Drug Discovery Solution launch.

The company's website features resource centers, product demos, case studies from pharmaceutical customers, and educational content on topics like GxP compliance, ELN selection, and laboratory data management. Blog content addresses practical topics like LIMS vs ELN comparisons, organizational growth planning, and modern ELN capabilities.

Press release activity includes product launches, customer implementations (Charles River, Euroscreen, Krystal Biotech), academic partnership announcements, and major corporate events like the Siemens acquisition. The company maintains a social media presence. Engagement metrics are undisclosed.

News coverage includes the March 2021 Insightful Science acquisition of Dotmatics ($690 million), the April 2022 rebranding to Dotmatics, and the April 2025 Siemens acquisition announcement ($5.1 billion). Industry publications including Drug Discovery World, GenomeWeb, Science Board, and Fierce Biotech have covered company developments.

The platform spans multiple scientific disciplines (chemistry, biology, materials science, flow cytometry), with cloud-first architecture, instrument integration (100+ devices), and compliance features for regulated industries.